Supporting Families. Saving Lives.
Sign-up for our Enewsletter here.
The purpose of the study is to evaluate an investigational drug for use in patients with LQT3, as it is believed that the risk of life-threatening cardiac events in patients with LQT3 is related to QT prolongation.
The study will consist of approximately 6 months of treatment, and will include multiple clinic visits during the course of the study. If eligible, participants may receive compensation for time and effort. Travel reimbursement will be provided to participants and an optional accompanying companion.
For more information, please visit clinicaltrials.gov or email LQT3@gilead.com.